Our first scientific paper on NSKIs has been published, in the prestigious medical journal Inflammatory Bowel Diseases:
Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders
Hagan, Suzanne; Fyfe, Matthew C. T.; Ofori-Frimpong, Boatemaa; Oliver, Katherine; Foster, Martyn R.; Sirohi, Sameer; Solanke, Yemisi; Doughty, Michael; Rowley, Adele; Taylor, Mike; Webber, Steve; Walshe, Claire A.
Investigative Opthalmology & Visual Science: March 2018 - Volume 59 - p1443-1453
A review paper has also been published by Matthew C.T. Fyfe, Non-systemic Intestine-Targeted Drugs. In: Geoff Lawton and David R. Witty, editors, Progress in Medicinal Chemistry, Vol. 55, Amsterdam: Elsevier, 2016, pp. 1-44
TopiVert presented the following poster at the 13th Congress of ECCO, 14-17 February 2018 in Vienna
A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of TOP1288, a Narrow Spectrum Kinase Inhibitor, delivered topically to the colon via oral administration
TopiVert presented the following 2 posters at ARVO, 7-11 May 2017 in Baltimore, MD
TopiVert presented the following 3 posters at the leading gastrointestinal industry conference: 12th Congress of ECCO, 15-18 February 2017 in Barcelona.
TopiVert presented the following 5 posters at the 11th Congress of ECCO, 16-19 March 2016 in Amsterdam
Inhibition of cytokine release from HT-29 cells and ulcerative colitis biopsies is potentiated by combination of selective kinase inhibitors and such effects are mimicked by TOP1210, a Narrow spectrum kinase inhibitor (NSKI)
TopiVert presented the following poster at DDW, 18-21 May 2013 in Orlando, FL